Allurion Q3 revenue $18.2M (+13% YoY), loss $26.2M; completes AUDACITY trial enrollment

ALLURION TECHNOLOGIES, INC.

2023-Q3 EPS reported -$2.00 revenue$45,232,000

Revenue $18.2M, up 13% YoY and 40% sequentially from Q2 2023; gross profit 77%.
Loss from operations $26.2M, including $10M in business combination and stock-based comp expenses.
Cash balance $79.9M after NYSE listing in August 2023, raising $92M net proceeds.
Completed enrollment in AUDACITY FDA pivotal trial for Allurion Balloon; PMA submission planned.
Launched Coach Iris, a generative AI-powered 24/7 weight loss coach.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ALLURION TECHNOLOGIES, INC. reported the quarter ended September 30, 2023 results: revenue $18.2 million.

Period: the quarter ended September 30, 2023
Revenue: $18.2 million
Result: reported results

Exact text from the filing

Total revenue for the quarter ended September 30, 2023 was $18.2 million compared to $16.1 million for the same period in 2022, and $13.0 million for the second quarter of 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

ALLURION TECHNOLOGIES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-062465

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.